Clinical trials in Charlotte, NC

139 recruiting studies have a site in or near Charlotte, NC, North Carolina.

Top conditions here

All conditions

Showing 40 of 139 studies

RecruitingPhase 3NCT07654374

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Charlotte, NC · Durham, NC · Fayetteville, NC · +71 more sites

RecruitingPhase 3NCT03394365

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Sponsor: Pierre Fabre Medicament

Chapel Hill, NC · Charlotte, NC · Durham, NC · +37 more sites

RecruitingPhase 2NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Sponsor: National Cancer Institute (NCI)

Chapel Hill, NC · Charlotte, NC · Durham, NC · +112 more sites

RecruitingPhase 4NCT06972056

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

Sponsor: Mayo Clinic

Charlotte, NC · +34 more sites

RecruitingPhase 3NCT07404865

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Sponsor: Vor Biopharma

Charlotte, NC · Durham, NC · +45 more sites

RecruitingPhase 3NCT04965675

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

Sponsor: H. Lundbeck A/S

Charlotte, NC · +21 more sites

RecruitingPhase 2NCT05554393

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Charlotte, NC · Durham, NC · +172 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Charlotte, NC · Winston-Salem, NC · +52 more sites

RecruitingPhase 3NCT06819878

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Sponsor: Hoffmann-La Roche

Charlotte, NC · Fuquay-Varina, NC · Monroe, NC · +92 more sites

RecruitingPhase 3NCT07674654

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

Sponsor: Kallyope Inc.

Charlotte, NC · Greensboro, NC · +110 more sites

RecruitingPhase 3NCT06617325

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Sponsor: UCB Biopharma SRL

Charlotte, NC · +62 more sites

RecruitingPhase 3NCT05164172

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

Sponsor: H. Lundbeck A/S

Charlotte, NC · +19 more sites

RecruitingPhase 3NCT05897320

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Sponsor: H. Lundbeck A/S

Charlotte, NC · +14 more sites

RecruitingPhase 2NCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Chapel Hill, NC · Charlotte, NC · Durham, NC · +222 more sites

RecruitingPhase 4NCT06581328

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

Sponsor: Takeda

Charlotte, NC · Greenville, NC · Pinehurst, NC · +98 more sites

RecruitingPhase 2NCT07409181

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Sponsor: Boehringer Ingelheim

Charlotte, NC · Fayetteville, NC · +28 more sites

RecruitingPhase 3NCT06136559

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Sponsor: Merck Sharp & Dohme LLC

Charlotte, NC · Goldsboro, NC · +47 more sites

RecruitingPhase 3NCT06307652

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

Sponsor: AstraZeneca

Asheville, NC · Chapel Hill, NC · Charlotte, NC · +163 more sites

RecruitingPhase 3NCT06307665

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

Sponsor: AstraZeneca

Charlotte, NC · Durham, NC · +118 more sites

RecruitingPhase 3NCT06312176

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Sponsor: Merck Sharp & Dohme LLC

Charlotte, NC · +45 more sites

RecruitingPhase 3NCT06430801

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Sponsor: Merck Sharp & Dohme LLC

Chapel Hill, NC · Charlotte, NC · +84 more sites

RecruitingPhase 2NCT06672146

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Charlotte, NC · Durham, NC · Greenville, NC · +132 more sites

RecruitingNot applicableNCT06965504

INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery

Sponsor: Abiomed Inc.

Charlotte, NC · Durham, NC · Winston-Salem, NC · +14 more sites

RecruitingPhase 2NCT06977581

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

Sponsor: Pfizer

Charlotte, NC · Gastonia, NC · Huntersville, NC · +33 more sites

RecruitingPhase 3NCT06989112

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Sponsor: AstraZeneca

Charlotte, NC · Winston-Salem, NC · +60 more sites

RecruitingPhase 3NCT07128199

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Sponsor: Taiho Oncology, Inc.

Charlotte, NC · Durham, NC · +28 more sites

RecruitingPhase 3NCT07225504

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Charlotte, NC · Raleigh, NC · +41 more sites

RecruitingPhase 3NCT07325292

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

Sponsor: Sanofi

Charlotte, NC · Raleigh, NC · +32 more sites

RecruitingPhase 3NCT07621809

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

Sponsor: Novartis Pharmaceuticals

Charlotte, NC · Wilmington, NC · +18 more sites

RecruitingPhase 1 / Phase 2NCT06546670

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Sponsor: Novartis Pharmaceuticals

Charlotte, NC · Greenville, NC · +7 more sites

RecruitingPhase 3NCT06878261

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

Sponsor: AstraZeneca

Charlotte, NC · Concord, NC · Fayetteville, NC · +77 more sites

RecruitingPhase 2NCT06972446

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

Sponsor: AbbVie

Charlotte, NC · +47 more sites

RecruitingPhase 3NCT07037433

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Sponsor: Amgen

Charlotte, NC · Durham, NC · Greensboro, NC · +137 more sites

RecruitingPhase 2NCT07745361

Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

Sponsor: Monte Rosa Therapeutics, Inc

Charlotte, NC · +13 more sites

RecruitingPhase not listedNCT03998202

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

Sponsor: Wake Forest University Health Sciences

Charlotte, NC · +144 more sites

RecruitingPhase 1NCT04429542

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Sponsor: Bicara Therapeutics

Charlotte, NC · +14 more sites

RecruitingPhase 3NCT06790693

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Sponsor: Hoffmann-La Roche

Charlotte, NC · Durham, NC · Winston-Salem, NC · +59 more sites

RecruitingPhase 2NCT06808984

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Sponsor: Celgene

Charlotte, NC · Raleigh, NC · +58 more sites

RecruitingPhase 3NCT07355218

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

Sponsor: EMD Serono Research & Development Institute, Inc.

Charlotte, NC · Smithfield, NC · +12 more sites

RecruitingNot applicableNCT07069738

Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

Sponsor: Boston Scientific Corporation

Charlotte, NC · Durham, NC · +40 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.